Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex Science Is Detailed — A Great Future

I just took an hour and scrutinized the new Anavex quarterly report. As a biologist I focused particularly on the presented science, pp. 25 through 29.

Exceptionally complete layouts of the discovered and clinically authenticated and demonstrated therapeutic applications and outcomes of the company's several novel, proprietary molecules.

The posting of comments on Anavex, or the taking or disposal of an AVXL stock position without carefully reading and comprehending the information in the quarterly report would seem unwise. Understanding the complexities of the unique science of the company's sigma-1 receptor agonists and how they can be useful therapeutic agents can be difficult. All of this is laid out in both the company's website, and in a more condensed (but yet detailed) form here in the quarterly report.

For me, once again, it was a reassuring read. 'Tis but a matter of time before the positive clinical results from the Parkinson's disease dementia study and the big Alzheimer's trial are released. With those data, blarcamesine will gain regulatory approval, in either the US (the FDA) or Australia (the TGA, Therapeutic Goods Administration). All of this should happen before 2023 ends.

Of course, as always, critical comments on any of the specific science points presented are warmly invited. Please, delineate any errors in what the company presented. If there are none, the company's future looks to be exceptionally bright.